There is increasing awareness of bronchiectasis in children and adolescents, a chronic pulmonary disorder associated with poor quality-of-life for the child/adolescent and their parents, recurrent exacerbations and costs to the family and health systems. Optimal treatment improves clinical outcomes. Several national guidelines exist, but there are no international guidelines.The European Respiratory Society (ERS) Task Force for the management of paediatric bronchiectasis sought to identify evidence-based management (investigation and treatment) strategies. It used the ERS standardised process that included a systematic review of the literature and application of the GRADE approach to define the quality of the evidence and level of recommendations.A multidisciplinary team of specialists in paediatric and adult respiratory medicine, infectious disease, physiotherapy, primary care, nursing, radiology, immunology, methodology, patient advocacy and parents of children/adolescents with bronchiectasis considered the most relevant clinical questions (for both clinicians and patients) related to managing paediatric bronchiectasis. Fourteen key clinical questions (7 "Patient, Intervention, Comparison, Outcome" [PICO] and 7 narrative) were generated. The outcomes for each PICO were decided by voting by the panel and parent advisory group.This guideline addresses the definition, diagnostic approach and antibiotic treatment of exacerbations, pathogen eradication, long-term antibiotic therapy, asthma-type therapies (inhaled corticosteroids, bronchodilators), mucoactive drugs, airway clearance, investigation of underlying causes of bronchiectasis, disease monitoring, factors to consider before surgical treatment and the reversibility and prevention of bronchiectasis in children/adolescents. Benchmarking quality of care for children/adolescents with bronchiectasis to improve clinical outcomes and evidence gaps for future research could be based on these recommendations.

Task Force report: European Respiratory Society guidelines for the management of children and adolescents with bronchiectasis / Chang, Anne B; Fortescue, Rebecca; Grimwood, Keith; Alexopoulou, Efthymia; Bell, Leanne; Boyd, Jeanette; Bush, Andrew; Chalmers, James D; Hill, Adam T; Karadag, Bulent; Midulla, Fabio; Mccallum, Gabrielle B; Powell, Zena; Snijders, Deborah; Song, Woo-Jung; Tonia, Thomy; Wilson, Christine; Zacharasiewicz, Angela; Kantar, Ahmad. - In: EUROPEAN RESPIRATORY JOURNAL. - ISSN 0903-1936. - (2021). [10.1183/13993003.02990-2020]

Task Force report: European Respiratory Society guidelines for the management of children and adolescents with bronchiectasis

Midulla, Fabio;
2021

Abstract

There is increasing awareness of bronchiectasis in children and adolescents, a chronic pulmonary disorder associated with poor quality-of-life for the child/adolescent and their parents, recurrent exacerbations and costs to the family and health systems. Optimal treatment improves clinical outcomes. Several national guidelines exist, but there are no international guidelines.The European Respiratory Society (ERS) Task Force for the management of paediatric bronchiectasis sought to identify evidence-based management (investigation and treatment) strategies. It used the ERS standardised process that included a systematic review of the literature and application of the GRADE approach to define the quality of the evidence and level of recommendations.A multidisciplinary team of specialists in paediatric and adult respiratory medicine, infectious disease, physiotherapy, primary care, nursing, radiology, immunology, methodology, patient advocacy and parents of children/adolescents with bronchiectasis considered the most relevant clinical questions (for both clinicians and patients) related to managing paediatric bronchiectasis. Fourteen key clinical questions (7 "Patient, Intervention, Comparison, Outcome" [PICO] and 7 narrative) were generated. The outcomes for each PICO were decided by voting by the panel and parent advisory group.This guideline addresses the definition, diagnostic approach and antibiotic treatment of exacerbations, pathogen eradication, long-term antibiotic therapy, asthma-type therapies (inhaled corticosteroids, bronchodilators), mucoactive drugs, airway clearance, investigation of underlying causes of bronchiectasis, disease monitoring, factors to consider before surgical treatment and the reversibility and prevention of bronchiectasis in children/adolescents. Benchmarking quality of care for children/adolescents with bronchiectasis to improve clinical outcomes and evidence gaps for future research could be based on these recommendations.
2021
bronchiectasis; pediatrics; respiratory medicine
01 Pubblicazione su rivista::01a Articolo in rivista
Task Force report: European Respiratory Society guidelines for the management of children and adolescents with bronchiectasis / Chang, Anne B; Fortescue, Rebecca; Grimwood, Keith; Alexopoulou, Efthymia; Bell, Leanne; Boyd, Jeanette; Bush, Andrew; Chalmers, James D; Hill, Adam T; Karadag, Bulent; Midulla, Fabio; Mccallum, Gabrielle B; Powell, Zena; Snijders, Deborah; Song, Woo-Jung; Tonia, Thomy; Wilson, Christine; Zacharasiewicz, Angela; Kantar, Ahmad. - In: EUROPEAN RESPIRATORY JOURNAL. - ISSN 0903-1936. - (2021). [10.1183/13993003.02990-2020]
File allegati a questo prodotto
File Dimensione Formato  
Chang_ERS-guidelines_2021.pdf

accesso aperto

Tipologia: Documento in Post-print (versione successiva alla peer review e accettata per la pubblicazione)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 5.44 MB
Formato Adobe PDF
5.44 MB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1542556
Citazioni
  • ???jsp.display-item.citation.pmc??? 41
  • Scopus 91
  • ???jsp.display-item.citation.isi??? 72
social impact